Primordial germ cells (PGCs) form during early embryogenesis with a supply of maternal mRNAs that contain shorter poly(A) tails. How translation of maternal mRNAs is regulated during PGC development remains elusive. Here we describe a small-molecule screen with zebrafish embryos that identified primordazine, a compound that selectively ablates PGCs. Primordazine's effect on PGCs arises from translation repression through primordazine-response elements in the 3′ UTRs. Systematic dissection of primordazine's mechanism of action revealed that translation of mRNAs during early embryogenesis occurs by two distinct pathways, depending on the length of their poly(A) tails. In addition to poly(A)-tail-dependent translation (PAT), early embryos perform poly(A)-tail-independent noncanonical translation (PAINT) via deadenylated 3′ UTRs. Primordazine inhibits PAINT without inhibiting PAT, an effect that was also observed in quiescent, but not proliferating, mammalian cells. These studies reveal that PAINT is an alternative form of translation in the early embryo and is indispensable for PGC maintenance.
M
ajor questions surround the mechanisms of translation in the early embryo before zygotic genome activation, wherein virtually all mRNAs are maternally supplied and exhibit short poly(A) tails 1 . How such mRNAs are translated without the benefit of poly(A) tails, and how the appropriate mRNAs are selected for translation, remains unknown. One possibility is that alternative translational mechanisms may exist in early embryos to circumvent the dependence on polyadenylation seen with canonical translation. We sought insight into translation in the early embryo by studying primordial germ cells (PGCs), which are among the first recognizable cell types to emerge during embryogenesis 2 . In many animals, PGC development commences before the onset of maternal-to-zygotic transition (MZT), so the common transcriptional and epigenetic processes that govern much of embryonic development cannot be used to regulate early germ cell development. Instead, regulation of the stability, localization, and translation of maternally supplied mRNAs is thought to regulate the development of PGCs in zebrafish. Unfortunately, many of the factors contributing to these processes remain unknown. This may be due, at least in part, to the difficulty in acquiring PGCs in mammalian models. Although PGCs or PGC-like cells can be obtained from embryonic stem cells or induced pluripotent cells (iPS) [3] [4] [5] [6] [7] , current methods have very low efficiency. In addition, in vitro systems cannot replicate all the factors that orchestrate developmental processes of PGCs in a living organism, which are dominated by maternally supplied RNAs and proteins, as well as signals originating from somatic cells. The zebrafish is an excellent in vivo model for the study of PGCs because zebrafish embryos undergo rapid early development and enable facile visualization of PGCs 8, 9 . In zebrafish embryos before MZT, mRNAs generally possess much shorter poly(A) tails 1 . As a result, translation is thought to be repressed generally until the onset of cytoplasmic polyadenylation (CPA), which stimulates translation by increasing the length of poly(A) tails on maternal mRNAs and allowing closed-loop formation. Although CPA is an important process for translation during early embryogenesis, more than half of maternal mRNAs (~60%) do not undergo CPA 10 , raising the possibility that an alternative mechanism of translation, independent of poly(A) tails may exist in early embryos to allow translation of deadenylated transcripts.
Here, we performed a chemical screen in zebrafish embryos with the goal of identifying small molecules that perturb establishment of the PGC lineage (Fig. 1a) . We identified a small molecule we named primordazine that causes selective ablation of PGCs, with other cell types being seemingly unaffected. We discovered that primordazine's underlying mechanism of action is translational repression, mediated by the 3′ UTRs of specific genes. Moreover, we provide evidence that translation of mRNA during early embryo development is mediated by at least two distinct pathways: canonical, primordazine-insensitive translation in the case of polyadenylated mRNAs, and noncanonical, primordazine-sensitive translation in the case of deadenylated, primordazine-response element (PRE)-containing mRNAs. These PRE-containing target mRNAs, for example nanos3 and deadend1 (dnd1), are sequestered in abnormal granules upon primordazine treatment. Thus, phenotypic screening has identified a small molecule capable of disrupting PGC development, thereby uncovering a fundamental translational mechanism.
Results
Discovery of primordazine, a compound that ablates PGCs. More than 7,000 structurally diverse compounds were screened using embryos from a transgenic zebrafish line 11 expressing EGFP in its PGCs (Supplementary Table 1 ). Two compounds caused disappearance of PGCs in the developing embryo without visibly causing changes in other cell types. Interestingly, the two compounds were structurally similar to each other, and we therefore named them primordazine A (1 ) and primordazine B (2 ) (prim-A and prim-B, respectively). A third compound, 3 (6364997), did not show any effect on PGCs despite structural similarity (Fig. 1b) . PGC loss was confirmed by in situ hybridization (ISH) with PGC markers ddx4 (ref. 12 ), nanos3 (ref. 13 ), and deadend1 (dnd1) 14 and by immunohistochemistry using anti-DDX4 antibody (Fig. 1c-g ). We found that PGCs begin to disappear 10-12 h post fertilization (hpf; Fig. 1d-g ). Although we occasionally observed a complete loss of PGCs by EGFP fluorescence or ISH, a few PGCs typically remained after primordazine treatment. Prim-A robustly decreased PGC numbers at 5-10 μ M without noticeable toxicity ( Supplementary Fig. 1 ). At concentrations of 20 μ M or higher, prim-A caused noticeable toxicity or developmental delay. Prim-B showed somewhat greater potency (Fig. 1b) with reduced toxicity compared to prim-A ( Supplementary Fig. 2 ). In addition, we found that early treatment between 2 to 5 hpf was essential for primordazine's activity ( Supplementary Fig. 3 ), suggesting that primordazine's effect on PGCs is mediated by a process occurring before 5 hpf. In addition, we tested whether the short exposure to primordazine during embryogenesis may impact sex determination or fertility in adult fish. Interestingly, we found that primordazine increases, in a dose-dependent way, the percentage of embryos that become male, consistent with previous studies showing that the number of PGCs affects sex determination in zebrafish [15] [16] [17] [18] ( Supplementary Fig. 4 ). Both male and female fish treated with prim-B remain fertile, suggesting that the few residual PGCs are sufficient to maintain fertility.
To test whether PGC loss is due to impairment of specification or migration, we examined PGCs at 3 hpf for specification and at 18 hpf for migration. We observed no reduction in PGC number at 3 Compounds were applied to each well at ~10 μ M and incubated for 24 h. The number of PGCs with EGFP expression was visually assessed. Hits were defined as compounds that reduced PGC numbers without visibly affecting other cell types. Scale bars, 100 μ m. b, Primordazine A and B were identified as inducing a dose-dependent decrease in the number of PGCs. However, 6364997 does not affect PGC number despite its structural similarity to primordazine. (n = 20 animals per condition for 1 and 2, n = 10 animals for 3). c, Treatment with prim-A results in loss of PGCs labeled by WISH with three PGC markers, ddx4, nanos3, and dnd1, in embryos at 24 hpf. This experiment was repeated two times with similar results. Scale bars, 100 μ m. d-g, Time-course analysis of WISH for the three PGC markersddx4 (d), nanos3 (e), and dnd1 (f)-shows that the number of PGCs begins to decrease around 9-10 hpf, whereas immunostaining for DDX4 indicates that PGC number drops from around 15 hpf (g). (n = 10 animals per condition/time point). Data in b and d-g is shown as mean ± s.e.m.
hpf and no ectopic PGCs at 18 hpf, indicating that PGC loss does not result from deficits in specification or migration ( Supplementary  Fig. 5a ). Because PGCs develop within the mesoderm, we tested whether primordazine causes abnormal mesoderm by ISH for gsc 19 , ta 20 , and pax2a 21 and found no abnormalities, suggesting that PGC loss after primordazine treatment is not due to defects in mesodermal patterning ( Supplementary Fig. 5b ).
Another possible mechanism of primordazine's effect on PGCs could be a change of mRNA levels. To test this possibility, we performed RNA-seq with total RNA from embryos collected at 2 or 6 hpf with or without prim-B treatment. No difference in RNA levels between DMSO and prim-B conditions was observed. qRT-PCR analysis confirmed that RNA levels of dnd1, nanos3, and ddx4 were not significantly changed by prim-B. These results demonstrate that primordazine does not substantially alter RNA levels in embryos ( Supplementary Fig. 6a-e) . We also tested whether primordazine induces PGC apoptosis and found no positive TUNEL staining within the genital ridge in prim-A-or prim-B-treated embryos. Another active primordazine analog, 5919059 (4 ), did show some TUNEL positivity, however, with random distribution, suggesting general toxicity rather than PGC apoptosis. Immunostaining for active caspase 3, a marker for apoptosis, was not observed in prim-B-treated embryos at 12 hpf ( Supplementary Fig. 7a-c) . Furthermore, we found that injection of antiapoptotic gene bcl2l mRNA or antisense morpholino oligonucleotide (MO) against proapoptotic gene tp53 failed to prevent PGC loss ( Supplementary  Fig. 7d ,e). We also found that PGC loss is not caused by exposure to hydrogen peroxide even at doses causing high embryonic mortality ( Supplementary Fig. 8 ). Together, these results suggest that the PGC loss caused by primordazine is not due to apoptosis or typical mechanisms of toxicity.
Primordazine inhibits translation via PRE in the 3′ UTR. To understand how primordazine causes a specific loss of PGCs, we tested whether primordazine inhibits translation of genes critical for PGC development, such as nanos3 (ref. 13 ). We injected EGFP mRNA fused to the nanos3-3′ UTR, causing EGFP to be expressed in PGCs. EGFP protein level was dramatically reduced by the primordazine treatment (Fig. 2a ), and the EGFP mRNA level remained unchanged ( Supplementary Fig. 6f ). We therefore hypothesized that a sequence element in the nanos3-3′ UTR could render translation of nanos3 sensitive to primordazine. To identify this sequence element, we tested various EGFP reporters. The nanos3-3′ UTR contains a target sequence for miR-430 that facilitates nanos3 mRNA decay in somatic cells but not in PGCs 22, 23 . However, we found that this site is not involved in primordazine function. We then tested a series of successive deletions across the 3′ UTR and discovered a 40-nucleotide sequence (i.e., 40-2) as a sufficient element for primordazine's response, which we named the PRE ( Fig. 2b; Supplementary Fig. 9 ). Although PRE-40-2 is sufficient to confer primordazine sensitivity, we used a larger 120-nucleotide sequence (PRE-120) for most studies because of its higher level of expression (Fig. 2c,d ).
Next, we tested whether primordazine can inhibit EGFP translation via the 3′ UTR of another PGC gene, dnd1 (ref. 14 ). Among three EGFP reporters containing three different regions of the dnd1-3′ UTR, EGFP-150-1 and EGFP-150-3 reporters showed significantly reduced EGFP protein levels upon prim-B treatment (Fig. 2e) . While examining different 3′ UTR fragments, we noticed that expression of EGFP reporters such as EGFP-120 and EGFP-150-1 could be observed throughout the entire body. Primordazine reduced translation of these constructs in somatic cells as effectively as in PGCs (Fig. 2c,e) , indicating that the fundamental machinery allowing primordazine's action exists throughout the early embryo.
Given the ability of primordazine to repress translation via the 3′ UTRs from nanos3 and dnd1, we examined whether exogenous expression of NANOS3 or DND1 could restore primordazineinduced PGC loss. Injection of polyadenylated mRNA of nanos3, dnd1, or both modestly but significantly attenuated primordazine's effect on PGC loss (Fig. 2f-h ), suggesting that PGC loss by primordazine is due in part to reduced translation of nanos3 and dnd1 and that there likely exist additional primordazine targets. Unfortunately, we could not monitor their protein levels by western blot because of the unavailability of antibodies for these proteins in zebrafish.
Next, we sought to determine whether primordazine is a general translational inhibitor. To that end, we tested the 3′ UTRs of eif3ha and ppp2cb by cloning them into a luciferase reporter. eIF3h regulates the development of the nervous and cardiovascular systems 24 .
Ppp2cb is a catalytic subunit of PP2A that is important for embryonic development and meiosis/mitosis 25 . Unlike the 3′ UTRs of nanos3 and dnd1, primordazine did not affect translation of mRNA bearing 3′ UTRs from eif3ha or ppp2cb (Fig. 2i) , indicating that primordazine is not a general translation inhibitor but rather acts via a specific subset of 3′ UTRs.
Embryos exhibit two distinct forms of translation. Translation can be regulated by a variety of mRNA structural features including the 5′ UTR, 3′ UTR, 5′ cap, and the poly(A) tail [26] [27] [28] . To test whether primordazine's action involves translation initiation factors, we appended three different internal ribosome entry site (IRES) sequences from three viruses-EMCV, HCV, or CrPV-to Renilla luciferase mRNA containing PRE-120 (hereafter, RLuc-120). The IRES sequences allow translation independent of the 5′ cap. EMCV IRES requires all initiation factors (eIFs) except for eIF4E. The HCV IRES requires fewer eIFs, whereas the CrPV IRES does not depend on any eIFs 26 . Primordazine significantly reduced translation of all three IRES reporters (Fig. 3a) . The independence of primordazine activity from the 5′ cap was further verified by the finding that primordazine blocked translation of RLuc-120 without a 5′ cap ( Supplementary Fig. 10a ). Additionally, we tested whether RNA helicase activity is important for primordazine's action by injecting RLuc-120 mRNAs carrying 5′ UTRs consisting of vector sequence alone, a structured β -globin stem-loop, or an unstructured (CAA) 18 sequence that does not require unwinding for translation 29, 30 . The translation from all three reporters showed a significant reduction upon treatment with prim-B (Fig. 3b,c) . These results indicate that primordazine inhibits translation independently of the 5′ cap, eIFs, and helicase activity.
We next tested the influence of polyadenylation on primordazine activity. Remarkably, whereas reporters without polyadenylation were highly sensitive to primordazine-induced translational repression, the polyadenylated reporters were completely resistant to primordazine (Fig. 3d) . We then asked whether polyadenylation affects primordazine's activity in a length-dependent manner or if it requires a certain minimal poly(A) length to obviate primordazine's effectiveness. Using a series of EGFP-120 reporters containing various lengths of a poly(A) tail, we found that the poly(A) tail works in a length-dependent manner, with polyadenylation diminishing the effect of primordazine ( Supplementary Fig. 11 ). Fitting of the resulting curve identified 72 as the number of adenosines at which primordazine's activity in translation inhibition is reduced by 50% (IA 50 ). Together, these results indicate that the mechanism of primordazine's action is independent of the 5′ cap, eIFs, and helicase activity, but is highly dependent on the presence of a 3′ PRE and the absence of polyadenylation.
The dramatic effect of poly(A)-tail length on sensitivity to primordazine caused us to hypothesize that at least two forms of translation occur in the early embryo: canonical, primordazineinsensitive translation in the case of polyadenylated mRNAs, and noncanonical, primordazine-sensitive translation in the case of deadenylated, PRE-containing mRNAs. We therefore tested the interaction of primordazine with rapamycin, a known inhibitor of canonical translation that functions by inhibiting mTOR activity 31, 32 . At saturating concentrations of rapamycin, when canonical translation initiation was maximally inhibited by rapamycin, addition of prim-B resulted in substantial further reduction in translation of a deadenylated, PRE-containing reporter (Fig. 3e) . However, when we used the luciferase reporter FLuc-SV40pA, containing a polyadenylated SV40-poly(A) signal (SV40) in the 3′ UTR, prim-B produced no translational inhibition beyond that achieved by rapamycin. These results provide additional evidence of two forms of translation in the early embryo. Primordazine does not affect translation that can be inhibited by rapamycin, which is a canonical, poly(A)-tail-dependent translation (PAT). However, translation of RLuc-120 involves a mechanism that is distinct from PAT and specifically inhibited by primordazine. We refer to this form of translation as PAINT (poly(A)-tail-independent noncanonical translation).
Following this observation of distinct, additive effects of rapamycin and primordazine on translation inhibition, we postulated that co-treatment with rapamycin and primordazine should enhance primordazine's effect on PGC loss. As predicted, embryos treated with prim-B and rapamycin possessed fewer PGCs compared to those treated with prim-B alone (Fig. 3f) . This effect was not due to general toxicity, as we didn't observe noticeable toxicity beyond a modest developmental delay ( Supplementary Fig. 12 ). We also observed a similar synergistic effect of torin2, a direct mTOR inhibitor 33 , on PGC loss ( Supplementary Fig. 13 ). Interestingly, treatment with rapamycin or torin2 alone did not affect PGC development, despite their inhibition of PAT, highlighting the importance of PAINT for PGC maintenance. 
Closed-loop formation protects mRNA from primordazine.
It is possible that polyadenylation protects mRNAs from primordazine through the actions of poly(A)-binding protein (PABP). Alternatively, polyadenylation may promote canonical translation by allowing formation of a canonical closedloop structure. To differentiate between these possibilities, we exploited a histone-3′ UTR containing a stem-loop that enables translation by forming a canonical closed loop without a poly(A) tail, thus making it independent of PABP 34 . We tested RLuc-120 reporters containing one or five stem-loops of histone-3′ UTR and found that increasing numbers of stem-loops confer proportional resistance to primordazine's activity (Fig. 3g,h ), suggesting that polyadenylation may protect transcripts from primordazine-mediated translational repression by enabling canonical closed-loop formation, not by recruiting PABP or via the poly(A) tail per se. Additionally, we confirmed that the inability of primordazine to inhibit PAT is independent of eIFs and the 5′ cap ( Fig. 3i; Supplementary Fig. 10b ).
Collectively, these results provide evidence for the existence of an alternative, primordazine-sensitive form of translation during early embryogenesis ( Supplementary Fig. 14) . PAINT is used by a subset of mRNAs with short poly(A) tails and may involve recruitment of . a, The translation of RLuc-120 (Renilla Luc) was significantly reduced by prim-B treatment despite the presence of an IRES in the 5′ UTR (n = independent experiments). P value for EMCV was calculated by a two-sided Mann-Whitney U-test. b, Luciferase reporters that contain different 5′ UTR structural elements. c, Primordazine inhibits translation independently of RNA structure in the 5′ UTR (n = 4 independent experiments). d, EGFP-120 or EGFP-150-1 mRNAs without a poly(A) tail exhibit a significant reduction in translation after prim-B treatment. However, the translation of the same mRNAs with a poly(A) tail (EGFP-120pA or EGFP-150-1pA) is unaffected by prim-B treatment. n = number of animals. e, Rapamycin (rapa) treatment results in a reduction of the expression of RLuc-120, but to a lesser extent than prim-B. Co-treatment with rapamycin and prim-B causes a further reduction in luciferase translation. In comparison, prim-B does not affect translation of FLuc-SV40pA containing a polyadenylated SV40 poly(A) signal in the 3′ UTR, whereas rapamycin substantially reduces it. In addition, co-treatment with rapamycin and prim-B does not show any additional effect on the translation of this reporter mRNA relative to rapamycin alone (n = independent experiments). f, Rapamycin synergistically reduces PGC number in the presence of prim-B, whereas rapamycin alone does not impact PGC maintenance (n = independent experiments). g, Luciferase reporters with one (1× SL) or five repeats (5× SL) of stem-loop from histone-3′ UTR. h, The presence of 5× SL completely abolishes primordazine's inhibition on translation, whereas 1× SL exhibits a partial reduction in primordazine's activity (n = independent experiments). i, Polyadenylation of IRES RLuc-120 reporters confers resistance to primordazine (n = independent experiments). *,**,***, versus DMSO; ##,###, versus prim-B; NS, not significant; *P < 0.05; **,##P < 0.01; ***,###P < 0.001. Unpaired two-sided t-test with 95% confidence intervals (c-f, h, and i). Box-and-whisker plots in a, c-f, h, and i show a median (centerline), upper/lower quartiles (box limits), maximum/minimum (upper/lower whiskers), and light blue dots (outliers).
RNA-binding proteins to specific sequence elements (for example, PRE) in their deadenylated 3′ UTRs. In contrast to PAT, PAINT can be inhibited by primordazine. Importantly, poly(A)-tail length is a major determinant of whether a transcript is translated by PAT or by PAINT.
Primordazine doesn't act by cytoplasmic polyadenylation. How PAINT enables translation in the absence of poly(A) tails remains unclear. CPA is known to increases the length of poly(A) tails of a subgroup of mRNAs during early embryogenesis. One possible explanation for primordazine's action could be that the PRE prioritizes its transcript for CPA, the resulting polyadenylation enables translation via PAT, and primordazine inhibits this process. To test this possibility, we injected embryos with cordycepin, an analog of adenosine that inhibits CPA. Despite its dramatic effect on embryonic development, PGC numbers were not affected ( Supplementary  Fig. 15a,b ). In addition, we injected embryos with RLuc-120 reporter chemically modified with cordycepin (A0) and found that prim-B was still able to inhibit translation of the A0 reporter ( Supplementary Fig. 15c ). Cytoplasmic polyadenylation elements (CPEs) are sequences that can target a transcript for CPA. We found that PRE-120 does contain two potential CPE sites. However, mutation of these CPEs didn't impact primordazine's action ( Supplementary Fig. 15d,e) . Furthermore, using an RNA-ligation-mediated poly(A) test and via qRT-PCR using oligo(dT), we found that PRE-120 does not undergo CPA despite containing these two putative CPEs ( Supplementary Fig. 15f,g ). Endogenous dnd1 and nanos3 mRNAs retain short poly(A) tails without CPA. By comparison, sox19b mRNA undergoes CPA, resulting in a significant increase in the length of its poly(A) tail. Interestingly, ddx4 mRNA exists with relatively long poly(A) tails without further lengthening by CPA. The long poly(A) tails on ddx4 mRNA likely confers its resistance to primordazine treatment. Together, these results demonstrate that CPA is not a factor for PAINT or for primordazine's mechanism of action.
Primordazine inhibits translation of a subset of mRNAs. Next, we investigated whether primordazine inhibits translation of endogenous dnd1, nanos3, and ddx4 mRNAs. We used TRAP (translating ribosome affinity purification) to evaluate translation efficiency using a zebrafish TRAP transgenic line expressing egfp-rpl10a 35 ( Fig. 4a) . We found that translation of dnd1 and nanos3 mRNAs was significantly reduced in the presence of prim-B, and their mRNA levels were unaffected. Meanwhile, translation of ddx4 mRNA was not affected by prim-B treatment (Fig. 4b,c) . In addition, translation of sox19b mRNA, which undergoes CPA, was not affected by primordazine. Therefore, translation of the endogenous mRNAs for dnd1, nanos3, ddx4, and sox19b corresponded to translation of the reporters bearing their 3′ UTRs.
To uncover additional endogenous target genes for primordazine, we performed 2D gel electrophoresis using difference gel electrophoresis ( Supplementary Fig. 16a,b) . Several spots showed noticeable differences in quantity between DMSO and prim-B conditions. The identities of these spots were difficult to determine unambiguously by MS because of contamination of yolk proteins and keratins and/or the presence of multiple proteins. Nevertheless, one spot was unambiguously identified as PGK1. Additionally, TRAP results showed that actively translated pgk1 mRNA is significantly reduced by prim-B treatment (Supplementary Fig. 16c ). Consistent with these results, we also found in Subtelny et al. 1 that the poly(A)-tail length of pgk1 mRNA remains very short up to 6 hpf ( Supplementary Fig. 16d ). Together, these results provide evidence that primordazine inhibits translation of a subgroup of endogenous mRNAs in the early embryo. Systematic discovery of additional primordazine-sensitive mRNAs will be a focus of future studies.
Primordazine causes the formation of RNA granules. Because translational repression and RNA granule formation are often linked 36, 37 and abnormal RNA-protein granule formation is associated with many diseases 38 , we tested whether primordazine affects mRNA distribution by fluorescence ISH (FISH). We found that nanos3 mRNAs are diffusely distributed in untreated embryos but become localized to abnormally large granules upon prim-B treatment (Fig. 5a,b) . We also observed similar granule formation for dnd1 mRNAs (Fig. 5c ). In contrast, we did not observe ddx4 mRNA granules upon primordazine treatment, suggesting that mRNAs sensitive to primordazine-induced translational repression are also prone to granule formation.
Given that polyadenylation prevents primordazine from inhibiting translation, we tested whether polyadenylation disturbs primordazine-induced RNA granule formation. To this end, we stained EGFP-120 or EGFP-120pA mRNA by FISH and found that primordazine indeed induced RNA granule formation of EGFP-120 but not EGFP-120pA mRNAs without causing a substantial change in their mRNA levels ( Supplementary Fig. 17 ). These results provide evidence for a link between translational repression and RNA granule formation.
We next attempted to characterize the location of primordazineinduced granules. We labeled germ granules by YFP fused to granulito, a germ granule marker 39 . Without primordazine, germ granules are relatively consistent in size, and most nanos3 mRNAs are localized outside of germ granules. In comparison, prim-B treatment induced abnormally large germ granules, some of which colocalized with nanos3 mRNA granules, suggesting that primordazineinduced translational repression causes aberrant redistribution of germ granules and target mRNAs in PGCs (Fig. 5d) .
Primordazine inhibits translation under select conditions.
Beyond the early embryo, there are several settings in which transcription or translation is repressed, where alternative forms of translation, such as PAINT, might play a role in gene control. Cells in quiescence 40, 41 are thought to have transcription, translation, or both repressed, but translation of specific transcripts may be necessary for cell survival or regrowth. Consistent with this idea, we observed that translation of PRE-containing reporters without a poly(A) tail was inhibited by primordazine in quiescent-like but not in proliferating mammalian cells, although their mRNA levels remain unaffected (Fig. 6a,b; Supplementary Fig. 18 ), suggesting that PAINT may occur outside the early embryo in the context of specific cell states (Fig. 6c) .
Discussion
The formation of a closed-loop in mRNA is a critical rate-limiting step in canonical translation. Traditionally, a poly(A) tail has been considered an obligatory structure for closed-loop formation and efficient canonical translation. However, whether mRNAs with short or no poly(A) tail can be effectively translated in vivo and whether poly(A)-tail-independent translation plays an important role in physiology have not been clear. Here we describe a novel compound, primordazine, that specifically ablates PGCs by inhibiting poly(A)-tail-independent noncanonical translation, PAINT, thereby providing in vivo evidence of the existence of PAINT and its physiological role in PGC maintenance. We also discovered that primordazine's ability to inhibit translation does not depend on the 5′ cap, eIFs, or helicase activity. Rather, specific sequence regions in the deadenlyated 3′ UTRs of target mRNAs are important for primordazine's action. Therefore, we collectively named these sequence elements PREs. Importantly, poly(A)-tail length appears to be a major determinant of whether a transcript is translated by canonical means (i.e., PAT) or by PAINT. Polyadenylation of deadenylated mRNAs that would normally be targets for primordazinemediated translational inhibition redirects them for PAT, rendering them resistant to primordazine.
It is interesting to speculate why the embryo might employ a noncanonical form of translation such as PAINT. One possibility is that it allows select mRNAs to be translated via an alternative pathway during a period of general translational repression. Most mRNAs become translationally repressed 42 during oocyte maturation, mainly due to deadenylation 43, 44 . Canonical translation isn't restored until mRNAs with long poly(A) tails are generated by CPA 45 or by zygotic transcription after MZT. Thus, genes such as nanos3 and dnd1, which must be translated early in embryogenesis, may not be efficiently translated by PAT because of their short poly(A) tails, but may be targeted for PAINT through the PREs in their 3′ UTRs. We expect that as embryos produce polyadenylated mRNAs after MZT, PAINT will become less active. This coordinated translation control may allow the embryo to accomplish precise spatiotemporal development via translation of select mRNAs. We have identified two genes, nanos3 and dnd1, master regulators of PGC identity that are translated via PAINT, and isolated elements in their 3′ UTRs that enable their noncanonical translation. Although we do not know how widespread the PAINT mechanisms are, we do know that primordazine-mediated translational inhibition can be observed in PGCs and somatic cells of the early embryo, suggesting that the mechanisms exist well beyond the PGC. Nevertheless, the most obvious phenotype resulting from inhibition of PAINT is a loss of PGCs. We speculate that PGCs may contain target genes for primordazine that are essential for PGC maintenance, whereas other cell types may have fewer essential genes that are targets for primordazine. In addition, it has been suggested that MZT may occur much later in PGCs than in somatic cells 46 , which may provide prolonged primordazine susceptibility of target mRNAs in PGCs. In the future, it will be interesting to examine in detail the effects of primordazine on somatic cells.
We found that cells in a quiescent-like state, but not those in proliferation, can utilize PAINT as an alternative form of translation (Fig. 6) , perhaps because general repression of canonical translation enables PAINT to be detectable. Similarly, we speculate that cells in other translationally repressive states such as viral infection 47 or stress conditions [48] [49] [50] may utilize PAINT to translate select mRNAs. Future work will focus on discovering other conditions in which PAINT occurs, understanding the molecular machinery of PAINT, identifying additional genes undergoing PAINT, and defining the characteristics of PREs that enable a transcript to undergo PAINT. We believe a better understanding of the mechanisms for PAINT will shed important light on developmental processes and disease settings where cells need to utilize this noncanonical translational mechanism.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41589-018-0098-0. Supplementary Fig. 19 . b, The translation of RLuc-120 was measured in two mammalian cell lines in the presence or absence of serum. Primordazine treatment inhibits the translation of RLuc-120 mRNA only in serum-free conditions. FLuc-SV40pA mRNA was used for normalization (n = independent experiments). Unpaired two-sided t-test. The box-and-whisker plot shows a median (centerline), upper/ lower quartiles (box limits), and maximum/minimum (upper/lower whiskers). c, Overview of the switch between canonical (PAT) and noncanonical (PAINT) translation in different cell states. While early zebrafish embryos have the ability to utilize both translation mechanisms, proliferating cells express proteins exclusively by canonical PAT. However, when cells switch into a quiescent-like state, noncanonical translation (PAINT) becomes activated. Importantly, primordazine only inhibits the noncanonical form of translation, PAINT, without inhibiting canonical PAT, leading to PGC loss in zebrafish embryos.
Fish husbandry. Adult zebrafish (Danio rerio) of the wild-type TuAB strain and the transgenic Tg(ddx4:EGFP) 11 and Tg(xef1α:EGFP-rpl10a) 35 lines were maintained in the fish facility at 28-29 °C with a 14/10 h light/dark cycle and were used for embryo production. 1:1-2 ratio of male and female fish were placed in a mating container and separated by a divider overnight. Embryos were collected after removing a divider in the morning and raised at 28. 11 , at the one-cell stage were placed in 200 μ l of E3 solution per well in 96-well plates that were not coated. 7,000 small molecules from the ChemBridge DiverSet library were added to each well at a concentration of ~10 μ M before 1 hpf. The plate was incubated at 28 °C in the dark overnight. The number of PGCs in embryos at ~24 hpf was visually assessed by EGFP fluorescence using a fluorescence stereomicroscope (Zeiss Discovery V8).
Small molecules. 1 (primordazine A), 2 (primordazine B), 3 (6364997), and 4 (5919059) were obtained commercially (Chembridge Corp.), and the identities and purities > 95% were confirmed by LC-MS.
Cell lines. F9 cells were acquired from ATCC (CRL-1720). DU145, H1573, and MCF7 cells were obtained from MGH cancer center. All of mammalian cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM l-glutamine, 1 mM sodium pyruvate, 5% FBS, 100 U/ml penicillin, and 100 μ g/ml streptomycin. F9 cells were cultured on dishes or plates coated with 0.1% gelatin (EMD Millipore). Transient transfections for RNA transfection was performed using Stemfect RNA transfection kit (Stemgent) or Lipofectamine MessengerMax (Invitrogen) according to the manufacturer's protocol. To induce quiescent-like cell state, cells were cultured in medium without serum about 24 h before transfection.
Plasmid construction and in vitro transcription. GFP constructs containing derivatives of the nanos3-3′ UTR with deletion or point mutations was kindly provided by K. Inoue (Kobe University) 23 and additional derivatives were made at EcoRI and XhoI sites. To make EGFP-120 mRNAs containing the different lengths of poly(A) tails, the 120 nucleotide upstream of nanos3-3′ UTR was inserted into EcoRI and XhoI sites of pTol2EGFPpA vector, which was made in our lab by engineering pCMV-Tag3B vector. A poly(A) tail with 5, 10, 20, 35, 50, 70, or 90 As was added into XhoI and MluI sites. The template plasmids were linearized by MluI and trimmed with Mung bean nuclease before in vitro transcription. The longer poly(A) tail, ~200 As, was made by the poly(A) tailing kit (Ambion). The full-length, 150-1, 150-2, and 150-3 3′ UTRs of dnd1 were amplified by PCR with cDNA from 8 hpf zebrafish embryos and cloned into HindIII and XhoI sites of pTol2EGFPpA. To make luciferase reporters, 120 of nanos3-3′ UTR or 150-1 of dnd1-3′ UTR was subcloned into XbaI and NotI sites of pRL-SV40 (Promega) to make Renilla luciferase reporter constructs. For the normalization of input amount of mRNAs, Luc2, a derivative of Firefly luciferase, from pGL4.14 (Promega) was amplified and inserted into BamHI and EcoRI sites of pTol2EGFPpA, named pTol2Luc2pA. MluI digestion was performed to linearize Luc2 plasmid for in vitro transcription. Luc2 mRNAs were polyadenylated after in vitro transcription and coinjected with Rluc-120 or Rluc-150-1 mRNAs at 30 ng/μ l. For the expression of dnd1 and nanos3, dnd1 (IMAGE clone ID: 7412116) was subcloned into EcoRI and SalI sites of pTol2mKate2pA which was engineered in our lab. Nanos3 (ATTC 10809379) was subcloned into EcoRI and XhoI sites of pCS2+ . The plasmid for bcl2l expression was previously described 51 . The plasmid of granulito-YFP was a kind gift of E. Raz 39 . To make Renilla reporters for the three IRESs, β-globin 5′ UTR, and CAA(18), 120 nucleotides were amplified by PCR and inserted into XbaI and NotI sites of parental plasmids kindly provided by M. Bushell (Medical Research Council) 29 . RL-120-hist3′ UTR(1 × SL) was made into HindIII and XhoI sites of RL-120 by inserting the PCR product of hist2h3c from a parental plasmid kindly provided by J. Wilusz
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. RL-120-hist3′ UTR(5 × SL) was generated by inserting 4 × SL gBlock (Integrated DNA Technologies) into EcoRI and HindIII sites of RL-120-hist3′ UTR(1 × SL). To make RNAs for injection, the plasmids were linearized with a specific restriction enzyme that cuts right after a SV40 poly(A) signal, or a derivative of nanos3-3′ UTR or dnd1-3′ UTR, and in vitro transcribed using the T3, T7, or SP6 mMESSAGE mMACHINE kit (Ambion). mRNAs without a 5′ cap were made using MAXIscript kit (Ambion).
Microinjection of RNAs or morpholinos (MOs) into zebrafish embryos.
MO for tp53 was obtained from GeneTools LLC (Corvallis, OR); tp53, gcgccattgctttgcaagaattg. 1 nl of 0.2 mM MO solution was injected into the yolk at the one-cell-stage embryos. For the expression of genes or GFP reporters, 1 nl of 100-500 ng/μ l mRNA was injected into one cell stage embryos. For Figs. 5d, 1 nl of 80 ng/μ l mRNA of EGFP-120 or EGFP-120pA was injected.
Luciferase assay. 1 nl of the mixture of 200 ng/μ l of a Renilla reporter mRNA and 20 ng/μ l of Luc2 mRNA with a poly(A) tail was injected into one-cell-stage embryos. 20-30 embryos at 6 hpf were collected into a 1.5 ml microtube. Embryos were washed with 1 ml of phosphate-buffered saline (PBS) and spun down for 30 s. The supernatant was discarded by aspiration. The lysates were made by adding 3 μ l of 1× passive lysis buffer per one embryo followed by homogenization with a plastic pestle. Upon centrifugation for 1 min, 20 μ l of solution was transferred to a well of an opaque 96-well plate. Firefly and Renilla luciferase activities were measured using the Dual-Glo Luciferase Assay (Promega) in a VICTOR X3 plate reader (PerkinElmer). The Renilla luciferase activity was normalized by the Firefly luciferase activity.
RNA extraction and qRT-PCR.
Approximately 30 embryos were collected at the indicated time point with or without drug treatment. Total RNA was extracted using Trizol (Invitrogen) or RNAzol RT (Molecular Research Center) according to the manufacturer's protocol. 1 μ g of total RNA was used to synthesize cDNA using random hexamers and the Superscript III First-Strand Synthesis System for RT-PCR (Invitrogen). The real-time PCR was performed using the Fast SYBR Green Master Mix (Applied Biosystems) and run on a 7500 Fast Real-Time PCR System machine (Applied Biosystems) in the fast mode. The relative amount of mRNAs was calculated by using the Δ Δ Ct (Ct, threshold cycle) method. The Ct value of ornithine decarboxylase 1 (odc1) was used for normalization. Primers are as follows: egfp forward 5′ -tcaagatccgccacaacatc-3′ , reverse 5′ -gtgctcaggtagtggttgtc-3′ ; nanos3 forward 5′ -tctgcagcttctgcaaacacaacg-3′ , reverse 5′ -gcagaatctcttggtgtgcgcttt-3′ ; dnd1 forward 5′ -tctgcaggaatggatgcagaggaa-3′ , reverse 5′ -actcgtaaatggtgccgatgctct-3′ ; ddx4 forward 5′ -acactgggagaagaggctttgg aa-3′ , reverse 5′ -tttccactctcatcaccaccacca-3′ ; sox19b forward 5′ -caacttcaccgg tacgatctg-3′ , reverse 5′ -cactgctgctgtaggacatt-3′ ; pgk1 forward 5′ -tggagtccctatgcc agacaaatac-3′ , reverse 5′ -tgcacaggctttctccacatctg-3′ ; odc1 forward 5′ -tgtccaat gaccgaaccctgatgt-3′ , reverse 5′ -ttgggtttcttgtgcagagttggc-3′ Rluc forward 5′ -tgggg tgcttgtttggcatttc-3′ , reverse 5′ -atcaggccattcatcccatgattc-3′ ; Luc2 forward 5′ -cttcga ggaggagctattcttg-3′ , reverse 5′ -gtcgtacttgtcgatgagagtg-3′ .
RNA-ligation mediated poly(A) test (RL-PAT).
2 µ g of mRNA was treated with RNaseH (New England BioLabs) in the presence or absence of oligo(dT) and ligated with YJ-P1 primer (5′ -ggtcactctatgatcgtacagc-3′ ) containing a 5′ phosphorylation and a 3′ amino modification using T4 RNA Ligase (New England BioLabs). The ligated RNA was reverse transcribed with YJ-P'1 (5′ -gctgtacgatcatagagtgacc-3′ ) using Superscript III First-Strand Synthesis System for RT-PCR (Invitrogen) according to the manufacturer's instructions. The PCR was performed using gene-specific forward and YJ-P'1 as reverse primer and the Hot Star GoTaq Polymerase (Promega). Gene-specific forward primers are as follows: egfp-F 5′ -tcaagatccgccacaacatc-3′ ; dnd1-F 5′ -tgagttgttttagtcagcctcatc-3′ ; nanos3-F 5′ -ctacaggcgcaaccgcactc-3′ ; ddx4-F 5′ -agctttgacctaaaggtgtttcc-3′ ; sox19b-F 5′ -ttgctgccacaaagttcgttc-3′ .
Translating ribosome affinity purification (TRAP). Tg(xef1α:EGFP-rpl10a)
transgenic line was obtained from the Dougherty lab 35 . Embryos from this transgenic fish line express EGFP-rpl10a, which is maternally deposited in the egg. Embryos at the 1-2 cell stage were treated with DMSO or 10 μ M prim-B. 100 μ g/ml cycloheximide (Acros Organics) was added to E3 solution 5 min before sample collection. 250 embryos at 3 hpf that showed bright EGFP fluorescence were pooled for each sample and E3 solution was removed. Embryos were snap frozen using liquid nitrogen. All polysome purification and mRNA extractions were performed as previously described with a slight modification 35, 53 . In brief, embryos were lysed in lysis buffer containing 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, pH 7.4), 5 mM MgCl 2 , 150 mM KCl, 1% NP-40, 0.5 mM DTT, 100 μ g/ml cycloheximide, 80 U/ml Ribolock (Thermo Scientific), and protease inhibitor cocktail (Pierce). The lysates were cleared by centrifugation at > 13,000 r.p.m. for 15 min at 4 °C. 10% of lysates were saved as pre-IP samples. The polysomes were immunoprecipitated using protein G magnetic beads (Pierce) that were coated with 100 μ g of mixed anti-GFP antibodies (clones 19C8 and 19F7) . Beads were washed four times with a high potassium buffer containing 20 mM HEPES (pH 7.4), 5 mM MgCl 2 , 350 mM KCl, 1% NP-40, 0.5 mM DTT, 100 μ g/ml cycloheximide, 40 U/ml Ribolock. Bound mRNAs were treated with DNaseI and extracted using Trizol-LS (Invitrogen). RNA concentration was determined using Qubit 3.0 (Invitrogen). 200 ng of pre-IP and 15 ng of IP RNA samples were used to synthesize cDNA. The qRT-PCR was performed as described in RNA extraction and qRT-PCR.
Illumina RNA sequencing. 30 embryos were collected at 2 or 6 hpf in the presence of DMSO or 10 μ M prim-B. RNA was extracted using RNAzolRT and purified with Direct-zol RNA kit (Zymo Research). The extracted RNA samples were treated with Ribo-Zero Gold rRNA Removal kit (Illumina) to deplete ribosomal RNAs (rRNAs) according to the manufacturer's protocol. Illumina RNA sequencing libraries were constructed using SMARTer Stranded RNA-Seq kit (Clontech) according to the manufacturer's protocol. Samples were multiplexed and sequenced on Illumina HiSeq 2500 machines to produce single-end 50-bp reads. To remove rRNAs reads, raw reads were filtered by SortmeRNA 54 using Silva database for Eukarya. The remaining reads were aligned to the zebrafish Zv9/danRer7 genome sequence using TopHat 2.1.0 with the default setting. Differential gene expression analysis was conducted with two biological replicates using SeqMonk Analyzer (Babraham Bioinformatics) and the R Bioconductor packages of DESeq2 (ref.
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) and edgeR 56 . All three different analyses failed to observe differentially expressed genes with statistical significance.
Whole-mount in situ hybridization (WISH) and fluorescence ISH (FISH).
The following probes were used for WISH: ddx4/vasa 12 , nanos3 (ref. 13 ), dnd1 (ref. 14 ), gsc 19 , ta/ntl 7 , and pax2a
21
. Full-length EGFP was used to make the probe. Anti-sense digoxigenin-labeled probes was obtained using DIG RNA labeling kit (Roche). Embryos at indicated post-fertilization time were dechorinated by 0.5-1 mg/ml of pronase and fixed in 4% paraformaldehyde (PFA) in PBS overnight at 4 °C. Embryos were washed with PBS containing 0.1% Tween-20 (PBST). After prehybridization in Hyb + solution (50% formamide, 5× SSC (1× SSC: 150 mM NaCl, 15 mM sodium citrate, pH 7.0), 0.1% Tween-20, 9 mM citric acid, 0.5 mg/ml yeast torula RNA, 0.1 mg/ml heparin, pH 6) for at least 2 h at 65 °C, embryos were then hybridized with 1-2 ng/μ l of RNA probe in Hyb + solution at 65 °C overnight. Embryos were washed twice with Hyb -solution (Hyb + solution without yeast torula RNA and heparin), twice with 2× SSC containing 0.1% Tween-20 (2× SSCT), twice with 0.2× SSC containing 0.1% Tween-20 (0.2× SSCT) at 65 °C and incubated with MABT (0.1 M maleic acid, 150 mM NaCl, 0.1% Tween-20, pH 7.5) with 2 mg/ml BSA and 5% sheep or goat serum) for 2-3 h at room temperature for blocking. For FISH, PBST containing 2 mg/ml BSA and 5% sheep or goat serum was used for blocking. The embryos were then incubated overnight at 4 °C with anti-digoxigenin antibody conjugated with alkaline phosphatase or peroxidase for WISH (Roche, 11 093 274 910) or FISH (Roche, 11 207 733 910), respectively. After several times washing with MABT, the substrates NBT/BCIP (Roche) were incubated with the embryos until the staining was developed to an optimal level. Staining was washed twice with PBST, once with methanol, and three times with PBST. For FISH, embryos were washed once with PBS, incubated for 8 min in TSA plus cyanine 3 solution (PerkinElmer), and washed five times with PBST.
2D gel electrophoresis (2D-GE).
At least 5,000 embryos for each condition were collected at about 5 hpf or between 40-50% epiboly after treatment of DMSO or 10 μ m prim-B from 0.5 hpf. Dechorionating and deyolking embryos was carried out as previously described 57 . Cell pellets were frozen in liquid nitrogen until use. Cells were lysed in 100 μ l of lysis buffer containing 10 mM HEPES (pH 7.4), 150 mM NaCl, 10 mM KCl, 1.5 mM MgCl 2 , 5% glycerol, 0.5% Triton X-100, 0.2% SDS, and protease inhibitor cocktail (Pierce). After sonication, insoluble particles were removed by centrifugation at 13,000 r.p.m. for 10 min. Protein concentration was determined by BCA assay (Pierce). 2D-GE was performed as shown in previous references 57, 58 . Briefly, 50 μ g of protein from each condition was processed with 2D Clean-up Kit (Bio-Rad), labeled by Cy3 or Cy5 dye (Lumiprobe) for DIGE (difference gel electrophoresis), and merged after quenching with 10 mM lysine. The merged sample was subjected to the first dimension isoelectric focusing using 11 cm pH 3-10 nonlinear IPG strip (Bio-Rad) in Protean IEF Cell power supply (Bio-Rad), followed by the second dimension SDS-PAGE with 10% polyacrylamide gels. DIGE gel images were obtained with a Typhoon Trio Laser scanner (GE Healthcare). To minimize experimental variation during DIGE, color swapping was carried out by switching Cy dyes between samples. Protein spots that showed noticeable difference in fluorescence intensity between the two Cy dyes were chosen for mass spectrometric analysis. For the preparative gels, 300 μ g of protein sample was loaded onto 17 cm pH 3-10 nonlinear IPG strip (Bio-Rad) and stained using an enhanced colloidal Coomassie blue. Spots of interest were excised and subjected to in-gel tryptic digestion for mass spectrometry.
Western blot, immunocytochemistry, and TUNEL. Cells transfected with EGFP reporter mRNAs were harvested 1 d after transfection. Cell lysates were washed with ice-cold PBS and lysed with lysis buffer containing 10 mM HEPES pH 7.4, 150 mM NaCl, 10 mM KCl, 1.5 mM MgCl 2 , 0.1% Triton X-100, 0.1% SDS, 5% glycerol, and cocktails of protease inhibitor and phosphatase inhibitor (Roche). Proteins were separated by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membrane. The membrane was blocked with 5% skim milk in Trisbuffered saline containing 0.05% Tween-20 (TBST) and incubated with the specific antibodies (1:5,000 dilution of anti-GFP (Torrey Pines Biolabs, TP401); 1:10,000 dilution of anti-tubulin (EMD Millipore, 05-829)) in TBST containing 2% BSA at 4 °C overnight. After washing three to four times, HRP-conjugated secondary antibody (1:5,000) in TBST containing 5% skim milk was applied and washed after 1 h. The blots were visualized by chemiluminescence using ECL Prime (GE Healthcare). Immunocytochemistry for activated caspase-3 was performed as previously described 59 . Briefly, embryos at 12 hpf were dechorionated with pronase, fixed with 4% PFA, permeabilized with ice-cold methanol followed by 1× PDT (1× PBST, 0.3% Triton-X, 1% DMSO), blocked in 1× PBST containing 2 mg/ml BSA and 10% FBS, and incubated with anti-activated caspase-3 (BD Biosciences, No. 559565) at 1:500 at 4 °C overnight. After washing with 1× PDT embryos were labeled with Alexa 555 anti-rabbit (Thermo Scientific). TUNEL was performed as previously described 60 .
Imaging and data analysis. The z-stack images of embryos for FISH or immunostaining were acquired at 40× objective on a Zeiss Axio Observer Z1 microscope using the LSM700 scanning system. Nuclei were stained with DAPI (4′ , 6-diamidino-2′ -phenylindol, dichloride, Thermo Scientific). All confocal images were processed into maximum intensity projections of z-stacks, unless otherwise stated. Confocal data were processed using Zen software (Zeiss) and FIJI/ImageJ (http://rsbweb.nih.gov/ij/). To obtain the images of WISH or of the wide-field fluorescence for the whole embryos, Discovery V8 stereomicroscope (Zeiss) was used with a 6.3× objective. PGC numbers were counted by GFP fluorescence from dechorionated Tg(ddx4:EGFP) embryos that were gently flattened by a coverslip to spread out PGCs.
Statistics and reproducibility.
All results are expressed as mean ± s.e.m., unless otherwise stated. Box-and-whisker plots show a median (centerline), upper/lower quartiles (box limits) and maximum/minimum (upper/lower whiskers). Statistical significance was determined using an unpaired two-tailed t-test, unless otherwise stated. P < 0.05 was considered statistically significant. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Sample size
To compare PGC numbers between DMSO and drug conditions, sample size was estimated by G*Power program for t-test with means difference between two independent means, alpha (0.05) and power (0.9). For luciferase assays and RT-PCR, sample size was not calculated, because each biological replicate was made of at least more than 20 embryos.
Data exclusions We did not exclude data that show even unusual high variance, because zebrafish embryos show a great variability in PGC numbers. However, we discarded or ignored embryos with severe deformity or delayed development, which may lead to confounding results.
Replication
Replications for experimental findings are reliably reproducible.
Randomization Blinding
Embryos from the same clutch were randomly divided into DMSO or drug conditions, prior to treatment. Embryos injected with mRNAs were randomly divided into two dishes or more prior to treatment. Adult fish were randomly chosen for mating. Mating time was randomly set from 9 am to 2 pm, since zebrafish mating efficiency and PGC numbers can be affected by mating time.
Blinding was not done because it was impractical due to a large number of embryos and experimental complexities but we always randomized embryos for the control and drug treatment. In addition, we did not involve any clinical study or human samples that require a high demand of blinded experiment.
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